STAT3 and prostate carcinoma: As shown in Figure 4B, treatment of prostate cancer cells with ATR II (0, 50 and 100 μM) for 12 h inhibited the STAT3 and promoter activity reached up to 70 and 40% in DU145, whereas LNCaP was reached up to 60 and 12% compared to control.